EMA Authorised: Nustendi (bempedoic acid;ezetimibe) — Daiichi Sankyo Europe GmbH

View source ↗

Summary

The EMA has authorised Nustendi, a fixed-dose combination of bempedoic acid and ezetimibe, for hypercholesterolemia and related dyslipidemias, under Daiichi San…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemias
• Hypercholesterolemia

Drugs mentioned

• Nustendi (bempedoic acid; ezetimibe)

Snippet

Status: Authorised. Therapeutic area: Hypercholesterolemia;Dyslipidemias. MAH: Daiichi Sankyo Europe GmbH. Decision date: 15/01/2026